Clinical and laboratory features of jak2 v617f, calr, and mpl mutations in Malaysian patients with classical myeloproliferative neoplasm (Mpn)
Authors
Zulkeflee, Razan HayatiZulkafli, Zefarina
Johan, Muhammad Farid
Husin, Azlan
Islam, Md Asiful
Hassan, Rosline
Issue Date
2021-07-16
Metadata
Show full item recordAbstract
Mutations of JAK2V617F, CALR, and MPL genes confirm the diagnosis of myeloprolifera-tive neoplasm (MPN). This study aims to determine the genetic profile of JAK2V617F, CALR exon 9 Type 1 (52 bp deletion) and Type 2 (5 bp insertion), and MPL W515 L/K genes among Malaysian patients and correlate these mutations with clinical and hematologic parameters in MPN. Mutations of JAK2V617F, CALR, and MPL were analyzed in 159 Malaysian patients using allele-specific polymerase chain reaction, including 76 polycythemia vera (PV), 41 essential thrombocythemia (ET), and 42 primary myelofibrosis (PMF) mutations, and the demographics of the patients were retrieved. The result showed that 73.6% JAK2V617F, 5.66% CALR, and 27.7% were triple-negative mutations. No MPL W515L/K mutation was detected. In ET and PMF, the predominance type was the CALR Type 1 mutation. In JAK2V617F mutant patients, serum LDH was significantly higher in PMF compared to PV and ET. PV has a higher risk of evolving to post PV myelofibrosis compared to ET. A thrombotic event at initial diagnosis of 40.9% was high compared to global incidence. Only one PMF patient had a CALR mutation that transformed to acute myeloid leukemia. JAK2V617F and CALR mutations play an important role in diagnostics. Hence, every patient suspected of having a myeloproliferative neoplasm should be screened for these mutations.Citation
Zulkeflee, R.H.; Zulkafli, Z.; Johan, M.F.; Husin, A.; Islam, M.A.; Hassan, R. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN). Int. J. Environ. Res. Public Health 2021, 18, 7582. https://doi.org/10.3390/ijerph18147582Publisher
MDPI AGJournal
International Journal of Environmental Research and Public HealthPubMed ID
34300032 (pubmed)Additional Links
https://www.mdpi.com/1660-4601/18/14/7582Type
Journal articleLanguage
enDescription
© 2021 The Authors. Published by MDPI. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.3390/ijerph18147582EISSN
1660-4601Sponsors
This research were funded by Universiti Sains Malaysia Postgraduate Publication Grant 1001/PPSP/8070011 and Research University Individual grant 1001/PPSK/8012213.ae974a485f413a2113503eed53cd6c53
10.3390/ijerph18147582
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International
Related articles
- Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN).
- Authors: Zulkeflee RH, Zulkafli Z, Johan MF, Husin A, Islam MA, Hassan R
- Issue date: 2021 Jul 16
- CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
- Authors: Ojeda MJ, Bragós IM, Calvo KL, Williams GM, Carbonell MM, Pratti AF
- Issue date: 2018 May
- Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
- Authors: Rabade N, Subramanian PG, Kodgule R, Raval G, Joshi S, Chaudhary S, Mascarenhas R, Tembhare P, Gujral S, Patkar N
- Issue date: 2018 Apr-Jun
- CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
- Authors: Kim SY, Im K, Park SN, Kwon J, Kim JA, Lee DS
- Issue date: 2015 May